Cargando…

Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations

The aim of this study was to analyze the risk of hypersensitivity reactions (HSRs) to iopromide in children and elderly patients in comparison to adults. MATERIALS AND METHODS: Four observational studies were pooled and analyzed (analysis I). In addition, spontaneous reports from 1985 to 2020 from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Endrikat, Jan, Chernova, Julia, Gerlinger, Christoph, Pracz, Marcin, Lengsfeld, Philipp, Bhatti, Aasia, Michel, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983946/
https://www.ncbi.nlm.nih.gov/pubmed/34860739
http://dx.doi.org/10.1097/RLI.0000000000000840
_version_ 1784682070886318080
author Endrikat, Jan
Chernova, Julia
Gerlinger, Christoph
Pracz, Marcin
Lengsfeld, Philipp
Bhatti, Aasia
Michel, Alexander
author_facet Endrikat, Jan
Chernova, Julia
Gerlinger, Christoph
Pracz, Marcin
Lengsfeld, Philipp
Bhatti, Aasia
Michel, Alexander
author_sort Endrikat, Jan
collection PubMed
description The aim of this study was to analyze the risk of hypersensitivity reactions (HSRs) to iopromide in children and elderly patients in comparison to adults. MATERIALS AND METHODS: Four observational studies were pooled and analyzed (analysis I). In addition, spontaneous reports from 1985 to 2020 from the pharmacovigilance database were evaluated (analysis II). All patients received iopromide for angiographic procedures or contrast-enhanced computed tomography in various indications. In analysis I, a nested case-control analysis, including a multivariable logistic regression model, based on pooled observational study data, was performed. Cases were defined as patients with a typical and unequivocal HSR; controls were patients without any recorded reaction. In analysis II, all spontaneous reports on HSRs after iopromide administration recorded in the pharmacovigilance database were descriptively analyzed. Exposure estimates on the size of the exposed age groups were derived from sales data and data from market research. The primary target variable was the risk of HSR to iopromide in children (<18 years) and elderly patients (≥65 years) compared with adults (≥18 to <65 years). RESULTS: In analysis I, a total of 132,850 patients were included (2978 children, 43,209 elderly, and 86,663 adults). Hypersensitivity reactions were significantly less frequent in children (0.47%) and elderly (0.38%) compared with adults (0.74%). The adjusted odds ratio (vs adults) for children was 0.58 (95% confidence interval, 0.34–0.98; P < 0.043), and that for the elderly was 0.51 (95% confidence interval, 0.43–0.61; P < 0.001), indicating a lower risk for both subpopulations as compared with adults. In analysis II, of the overall >288 million iopromide administrations, 5.87, 114.18, and 167.97 million administrations were administered to children, elderly, and adults, respectively. The reporting rate for HSRs in children (0.0114%) and elderly (0.0071%) was significantly lower as compared with adults (0.0143%) (P < 0.0001). CONCLUSIONS: Hypersensitivity reactions to iopromide were significantly less frequent in children and elderly compared with adults.
format Online
Article
Text
id pubmed-8983946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89839462022-04-13 Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations Endrikat, Jan Chernova, Julia Gerlinger, Christoph Pracz, Marcin Lengsfeld, Philipp Bhatti, Aasia Michel, Alexander Invest Radiol Original Articles The aim of this study was to analyze the risk of hypersensitivity reactions (HSRs) to iopromide in children and elderly patients in comparison to adults. MATERIALS AND METHODS: Four observational studies were pooled and analyzed (analysis I). In addition, spontaneous reports from 1985 to 2020 from the pharmacovigilance database were evaluated (analysis II). All patients received iopromide for angiographic procedures or contrast-enhanced computed tomography in various indications. In analysis I, a nested case-control analysis, including a multivariable logistic regression model, based on pooled observational study data, was performed. Cases were defined as patients with a typical and unequivocal HSR; controls were patients without any recorded reaction. In analysis II, all spontaneous reports on HSRs after iopromide administration recorded in the pharmacovigilance database were descriptively analyzed. Exposure estimates on the size of the exposed age groups were derived from sales data and data from market research. The primary target variable was the risk of HSR to iopromide in children (<18 years) and elderly patients (≥65 years) compared with adults (≥18 to <65 years). RESULTS: In analysis I, a total of 132,850 patients were included (2978 children, 43,209 elderly, and 86,663 adults). Hypersensitivity reactions were significantly less frequent in children (0.47%) and elderly (0.38%) compared with adults (0.74%). The adjusted odds ratio (vs adults) for children was 0.58 (95% confidence interval, 0.34–0.98; P < 0.043), and that for the elderly was 0.51 (95% confidence interval, 0.43–0.61; P < 0.001), indicating a lower risk for both subpopulations as compared with adults. In analysis II, of the overall >288 million iopromide administrations, 5.87, 114.18, and 167.97 million administrations were administered to children, elderly, and adults, respectively. The reporting rate for HSRs in children (0.0114%) and elderly (0.0071%) was significantly lower as compared with adults (0.0143%) (P < 0.0001). CONCLUSIONS: Hypersensitivity reactions to iopromide were significantly less frequent in children and elderly compared with adults. Lippincott Williams & Wilkins 2022-05 2021-12-03 /pmc/articles/PMC8983946/ /pubmed/34860739 http://dx.doi.org/10.1097/RLI.0000000000000840 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Articles
Endrikat, Jan
Chernova, Julia
Gerlinger, Christoph
Pracz, Marcin
Lengsfeld, Philipp
Bhatti, Aasia
Michel, Alexander
Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title_full Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title_fullStr Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title_full_unstemmed Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title_short Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million Administrations
title_sort risk of hypersensitivity reactions to iopromide in children and elderly: an analysis of 132,850 patients from 4 observational studies and pharmacovigilance covering >288 million administrations
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983946/
https://www.ncbi.nlm.nih.gov/pubmed/34860739
http://dx.doi.org/10.1097/RLI.0000000000000840
work_keys_str_mv AT endrikatjan riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT chernovajulia riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT gerlingerchristoph riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT praczmarcin riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT lengsfeldphilipp riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT bhattiaasia riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations
AT michelalexander riskofhypersensitivityreactionstoiopromideinchildrenandelderlyananalysisof132850patientsfrom4observationalstudiesandpharmacovigilancecovering288millionadministrations